SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-193424
Filing Date
2023-07-25
Accepted
2023-07-25 16:02:58
Documents
12
Period of Report
2023-07-20
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d428056d8k.htm   iXBRL 8-K 29467
  Complete submission text file 0001193125-23-193424.txt   154961

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA algs-20230720.xsd EX-101.SCH 2836
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20230720_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20230720_pre.xml EX-101.PRE 11698
6 EXTRACTED XBRL INSTANCE DOCUMENT d428056d8k_htm.xml XML 3481
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 231108554
SIC: 2836 Biological Products, (No Diagnostic Substances)